Genentech's EVP of research and early development Aviv Regev at #JPM23 (Adrien Villez for Endpoints News)

December 11, 2023 09:42 AM EST

Exclusive: Aviv Regev talks three years of leading Genentech’s research, the future of AI, and not making Nobel predictions

Andrew Dunn

Senior Biopharma Correspondent

SOUTH SAN FRANCISCO — In 2020, Aviv Regev ended an esteemed 14-year run at the Broad Institute to jump into the drug industry, becoming Genentech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Exclusive: Aviv Regev talks three years of leading Genentech’s research, the future of AI, and not making Nobel predictions

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Ex­clu­sive: Aviv Regev talks three years of lead­ing Genen­tech’s re­search, the fu­ture of AI, and not mak­ing No­bel pre­dic­tions

Senior Biopharma Correspondent

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Exclusive: Aviv Regev talks three years of leading Genentech’s research, the future of AI, and not making Nobel predictions